Navigation Links
Modified gene targets cancer cells a thousand times more often than healthy cells
Date:12/17/2008

Researchers at the University of Rochester have designed a gene that produces a thousand times more protein in cancer cells than in healthy cells.

The findings may help address the prime challenge in anti-cancer therapy: improving treatments' ability to specifically and effectively target cancer cells. Using this new approach, scientists should be able to insert "self-destruct" codes into the modified gene, forcing cancer cells to kill themselves while healthy cells remain largely unaffected.

Though trials will be necessary to determine if the difference is enough to destroy tumors without harming healthy tissue, the initial findings, published in today's early edition of Proceedings of the National Academy of Sciences, are promising, say the authors.

Vera Gorbunova, assistant professor of biology at the University of Rochester, and her team, Andrei Seluanov, assistant professor of biology, and graduate student Christopher Hine, were investigating Rad51, a protein that is expressed at about five times higher level in cancer cells than in healthy cells, when they stumbled on something very unexpected.

"We stripped off some of the Rad51 gene and replaced it with a marker protein DNA to see why Rad51 was five times more abundant in cancer cells," says Gorbunova. "We wanted to see if there was any way we could boost that difference and create a really useful cancer-targeting tool. We couldn't believe it when we saw the cancer cells expressing the engineered Rad51 around a thousand times more."

When Gorbunova first saw the huge discrepancy, she thought one of her graduate students had fumbled the lab test. Further tests showed that the altered Rad51 was expressed in some cancer cells as much as 12,500 times as often as healthy cells, says Gorbunova. Such a large discrepancy means scientists should be able to use it to create versions of Rad51 that carry a "toxic bomb," which only the cancer cells will trigger.

Rad51 is normally involve
'/>"/>

Contact: Jonathan Sherwood
jonathan.sherwood@rochester.edu
585-273-4726
University of Rochester
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Novel bioreactor enhances interleukin-12 production in genetically modified tobacco plants
2. Technique used in human ankle injuries modified to treat dogs knees
3. Genetically modified carrots provide more calcium
4. Penn Veterinary Medicine report new strategy to create genetically-modified animals
5. UQ research targets West Nile virus and dengue fever
6. New genes present drug targets for managing cholesterol and glucose levels
7. First comprehensive genomic study of common cold reveals new treatment targets
8. US Air Force grant targets medical evacuation procedures
9. Viral magic bullet targets cancer cells with help of new compound
10. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
11. N.Y. research team discovers how antidepressants and cocaine interact with brain cell targets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... cell, including sperm, bacteria and algae, propel themselves ... about one-hundredth of a millimetre long, function like ... shorter structures called cilia are found on the ... such as moving liquids over the cell. ... transport mucus and expel pathogens from our airways, ...
(Date:7/28/2014)... An international team of researchers led by the University ... rice. , The genetic information will enhance scientists, and ... as well as enable the development of new rice ... environmental stressors to help solve global hunger challenges. , ... Oryza glaberrima ) and evidence for independent domestication," was ...
(Date:7/28/2014)... rat brain cells suggests that the effects of a ... cells are temporary. , The study, published in this ... was conducted by biologists at the University of California, ... York in response to concerns, arising from multiple studies ... to general anesthetics may increase their susceptibility to long-term ...
Breaking Biology News(10 mins):Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3Generating a genome to feed the world: UA-led team sequences African rice 2Generating a genome to feed the world: UA-led team sequences African rice 3Generating a genome to feed the world: UA-led team sequences African rice 4Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3
... cancer has shown considerable promise in early clinical trials ... drugs. Chemists and biologists at ... Sloan-Kettering Cancer Center, have created a new drug to ... as castration-resistant prostate cancer, or CRPC. Also referred to ...
... of drug-resistant bacteria, called multidrug-resistant gram-negative (MDRGN) ... common antimicrobial-resistant infections in long-term care facilities, ... at Hebrew SeniorLife,s Institute for Aging Research., ... of the main reservoirs of antimicrobial-resistant bacteria. ...
... /PRNewswire-Asia/ -- Futronic Technology Company,Limited, a global provider of ... of FS90 USB2.0 Mini Fingerprint,Scanner. , ... deliver high quality image,in a very small form factor. ... and just,slightly larger than one half of Futronic FS80 ...
Cached Biology News:New drug shows promise in treating drug-resistant prostate cancer 2New drug shows promise in treating drug-resistant prostate cancer 3New drug shows promise in treating drug-resistant prostate cancer 4Study finds multidrug-resistant gram-negative bacteria high in long-term care 2Futronic Launches FS90 USB2.0 Mini Fingerprint Scanner 2
(Date:7/29/2014)... Hershey, PA & Rockville, MD (PRWEB) July 29, ... Immunomic Therapeutics, Inc. (ITI), a vaccine pioneer in ... the financial services firm Newport Coast Securities, Inc. ... , ITI is commercializing LAMP-vax technology, a breakthrough ... $25B+ vaccines and immunotherapy market. The company exclusively ...
(Date:7/29/2014)...  Sigma-Aldrich Corporation (NASDAQ: SIAL ) dramatically ... investment in Green Chemistry and donated more than 8,000 ... the Company announced Monday in its new 2013 ... The report comes in a year ... responsible corporate citizen, including recognition for the second consecutive ...
(Date:7/29/2014)...  United Therapeutics Corporation (NASDAQ: ... for the second quarter ended June 30, 2014. ... our medicines are reaching increasing numbers of ... said Martine Rothblatt, Ph.D., United Therapeutics, Chairman ... this quarter of our extended-release tablet called ...
(Date:7/29/2014)... July 29, 2014 Eppendorf Centrifuge ... product selection. Eppendorf 5427 R is geared towards high-end ... – it is targeted towards work requiring high sample ... R as it compliments their extensive 16, 48, and ... of microcentrifuge tubes, PCR tubes, PCR strip tubes, and ...
Breaking Biology Technology:Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2
... DJO Incorporated,(NYSE: DJO ), a global provider of ... reported that on August 9, 2007,the U.S. Federal Trade ... the Hart-Scott-Rodino Antitrust Improvements Act of,1976, as amended, for ... Therapeutics, Inc. ("ReAble"). On July 16, 2007, DJO ...
... Valeant Pharmaceuticals ... ... Biosciences,Inc. (Pink Sheets: ARDC) today announced that it has received the ... (NYSE: VRX ). In December 2006, Ardea Biosciences entered ...
... Shareholder Support for Vermed Sale, SAN DIEGO, Aug. ... innovator and leader of,impedance cardiography (ICG) technology, today announced ... progressing well with over 50%,of the necessary shareholder votes ... the Vermed sale. The ratio of votes,received is running ...
Cached Biology Technology:DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 2DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 3DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 4Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc. 2CardioDynamics Provides 2007 Shareholder Meeting Update 2CardioDynamics Provides 2007 Shareholder Meeting Update 3
... kit contains the basic components required for ... natural and recombinant rat Thymus Chemokine-1 in ... contains sufficient materials to run ELISAs on ... following conditions are met: The ...
Request Info...
SCP-1 (P-17)...
Rabbit polyclonal to Kallikrein 1 ( Abpromise for all tested applications). Antigen: Full length native kallikrein from tissue (Human) Entrez Gene ID: 3816 Swiss Protein ID: P06870...
Biology Products: